CAMPTO is contraindicated in patients with: A chronic inflammatory bowel disease and/or a bowel obstruction (see Precautions).
A history of severe hypersensitivity reactions to irinotecan hydrochloride trihydrate or to one of the excipients of CAMPTO (see Precautions).
In pregnant or breast feeding women.
In patient with bilirubin >3 times the ULN (see Precautions).
In patient with a severe bone marrow failure.
In patients presenting a risk factor, particularly those with a WHO performance status >2.